A shadow market for unlicensed weight-loss drugs is being driven by social media fitness personalities and sellers on messaging platforms, based on recent findings.
Investigational Drug Gaining Traction Via Social Media
Retatrutide, which is still in research studies, is being advertised by social media influencers for its supposed weight-reducing properties. Viewers are encouraged to message these accounts privately for source information, while also obtaining promotional offers.
Active Commerce on Social Networks
Additionally, a flourishing market exists on messaging services, where groups with thousands of participants share comparison images, administration instructions and assertions of rapid UK delivery. Sellers promote the substance there before redirecting customers to WhatsApp for transactions.
Learning About Retatrutide
Retatrutide is an experimental injection developed by American pharmaceutical company Eli Lilly. The drug targets three gut hormones – GLP-1, GIP and pancreatic hormone. Preliminary studies suggest it could assist patients reduce up to 25% of their total weight. Referred to as the “triple G”, the drug is being promoted digitally as the successor to Ozempic.
Healthcare Experts Express Concerns
Nevertheless, doctors and chemists have warned that the sale of what is still an unlicensed medication in the United Kingdom is worrisome and could result in users administering substances of unknown origin.
Some professionals stated the demand for the experimental drug could be linked to the rising price of licensed slimming treatments such as Mounjaro.
Regulatory Position and Implementation
Marketing the unapproved drug on social media or messaging apps is illegal in the United Kingdom, as it is an unlicensed drug that cannot be promoted or supplied for personal consumption under the British medical regulations.
Several content creators attempt to sidestep the rules by referring to the substance as a “research chemical” or describing it as “not for human consumption”. The substance is not a restricted substance, but advertising and distribution can still violate pharmaceutical, marketing, and consumer regulations, potentially leading to fines, prosecution or prison.
Platform Reaction and Content Elimination
Based on the social media company, the service has removed problematic content and prohibited related hashtags and query recommendations. The company said it was dedicated to keeping the service secure and allocating resources in enhancing enforcement strategies.
Digital Trading Activities
Research also found communities with up to 9,000 participants marketing the experimental drug using Telegram's built-in discovery tool, which functions like a public directory. Typing “retatrutide” instantly brings up groups with numerous of members, filled with images of weight loss, positive reviews and detailed instructions for preparing or administering at residence.
Within moments of entering one group, a vendor shared contact information, where the majority of transactions occur. The vendor provided an instruction manual and guaranteed shipping within 48 hours. When asked whether the product was genuine, one seller said: “You can’t be sure.” Another shared a photo of a supposed laboratory certificate. None inquired about weight, health issues or past usage.
Item Details and Costs
Inside these groups, messages show black plastic parcels with Royal Mail stickers, claiming to contain new batches. One communication stated: “It took eight of us to load them this morning.”
Customers can select between dry substance containers, mixed at residence with purified liquid, or pre-filled injectors usually sold at £160 for 20 milligrams. When asked how long a pen should be used, sellers give contradictory answers ranging from a several days to “depends on your body”.
Platform Oversight and Safety Measures
A spokesperson for Telegram stated it regularly moderated harmful material on its service including material that promoted the “misuse of controlled medications”. The organization added that it eliminated “millions of pieces of harmful content each day”.
Medical Professional Warnings
“Individuals are administering materials they cannot confirm. Even if the science behind this drug is sound, these online versions may not contain what they advertise,” stated a pharmacy expert, the head of pharmacy at a pharmacy service.
Dr Crystal Wyllie of Asda Online Doctor linked the increase in interest to recent cost increases for approved weight-loss medications such as Mounjaro. “With prices rising, patients are using social media. But fake treatments are highly dangerous. You cannot know what’s inside or whether the environment they were made in was clean,” she explained.
Her team has already encountered individuals harmed by self-injection from unconfirmed sources. “We understand the frustration, but buying from Telegram or communication platforms is taking chances with your well-being,” stated Wyllie. “These materials could be impure or improperly measured.”
Producer Position
A representative from the pharmaceutical company said retatrutide was in phase 3 research studies and had not been evaluated or authorized by any regulatory agency globally. “Consequently at this point no one can sell [it] for human use,” they explained, adding that any item “falsely representing itself as a company experimental product not yet authorized … may subject users to potentially serious medical dangers”.
